Preclinical News and Research

RSS

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

28 Mar 2011

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

FDA approves ipilimumab for metastatic melanoma treatment

The U.S. Food and Drug Administration announced today its approval of a new treatment for advanced melanoma, the deadliest and most difficult-to-treat form of skin cancer.

28 Mar 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

AACR to honor UNC scientist with $181,000 grant for breast cancer research

The American Association for Cancer Research announced today that Carey Anders, MD, assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center will receive a Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research. The $181,000 grant will be presented at the organization's 102nd Annual Meeting, to be held in Orlando, Florida, April 2-6.

28 Mar 2011

FDA approves ipilimumab to treat metastatic melanoma

The US Food and Drug Administration announced today that the drug ipilimumab has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

28 Mar 2011

FDA approves humanitarian device exemption for Elana Surgical Kit in cerebral bypass

Dutch medical device manufacturer, Elana bv, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a humanitarian device exemption (HDE), enabling a lifesaving cerebral bypass. Elana bv is a corporate spin-off from the University Medical Centre Utrecht, the Netherlands.

25 Mar 2011

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

Covaris launches Bench-top SF220 Formulation Processing System

Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

25 Mar 2011

EU supports new collaborative research projects on tuberculosis

It's March 24th again and the World Tuberculosis Day reminds us that for almost 50 years no new drugs have been developed against this terrible disease, which is currently killing nearly two million people worldwide each year. It's a global problem because the emergence of drug resistant strains of this infectious disease - normally associated with poverty - is a growing problem even in high-income economies.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

VisualSonics introduces Vevo LAZR system to advance cancer research

VisualSonics Inc., a leader in real-time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., today announced the launch of the Vevo LAZR Photoacoustics Imaging system for the advancement of cancer research in the pre-clinical imaging market.

25 Mar 2011